Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
PLoS One ; 16(9): e0257784, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34582497

RESUMEN

Drug repurposing has the potential to bring existing de-risked drugs for effective intervention in an ongoing pandemic-COVID-19 that has infected over 131 million, with 2.8 million people succumbing to the illness globally (as of April 04, 2021). We have used a novel `gene signature'-based drug repositioning strategy by applying widely accepted gene ranking algorithms to prioritize the FDA approved or under trial drugs. We mined publically available RNA sequencing (RNA-Seq) data using CLC Genomics Workbench 20 (QIAGEN) and identified 283 differentially expressed genes (FDR<0.05, log2FC>1) after a meta-analysis of three independent studies which were based on severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection in primary human airway epithelial cells. Ingenuity Pathway Analysis (IPA) revealed that SARS-CoV-2 activated key canonical pathways and gene networks that intricately regulate general anti-viral as well as specific inflammatory pathways. Drug database, extracted from the Metacore and IPA, identified 15 drug targets (with information on COVID-19 pathogenesis) with 46 existing drugs as potential-novel candidates for repurposing for COVID-19 treatment. We found 35 novel drugs that inhibit targets (ALPL, CXCL8, and IL6) already in clinical trials for COVID-19. Also, we found 6 existing drugs against 4 potential anti-COVID-19 targets (CCL20, CSF3, CXCL1, CXCL10) that might have novel anti-COVID-19 indications. Finally, these drug targets were computationally prioritized based on gene ranking algorithms, which revealed CXCL10 as the common and strongest candidate with 2 existing drugs. Furthermore, the list of 283 SARS-CoV-2-associated proteins could be valuable not only as anti-COVID-19 targets but also useful for COVID-19 biomarker development.


Asunto(s)
Tratamiento Farmacológico de COVID-19 , Reposicionamiento de Medicamentos/métodos , SARS-CoV-2/genética , Antivirales/uso terapéutico , Evaluación Preclínica de Medicamentos/métodos , Células Epiteliales/efectos de los fármacos , Epitelio/efectos de los fármacos , Humanos , Mucosa Respiratoria/efectos de los fármacos , Mucosa Respiratoria/metabolismo , Mucosa Respiratoria/virología , Sistema Respiratorio/efectos de los fármacos , SARS-CoV-2/efectos de los fármacos , SARS-CoV-2/patogenicidad
2.
BMC Musculoskelet Disord ; 11: 49, 2010 Mar 14.
Artículo en Inglés | MEDLINE | ID: mdl-20226091

RESUMEN

BACKGROUND: Despite the reported high prevalence of osteoporosis in India, there have been no previous studies examining the risk factors for hip fracture in the Indian population. METHODS: We carried out a case control investigation comprising 100 case subjects (57 women and 43 men) admitted with a first hip fracture into one of three hospitals across New Delhi. The 100 controls were age and sex matched subjects who were either healthy visitors not related to the case patients or hospital staff. Information from all subjects was obtained through a questionnaire based interview. RESULTS: There was a significant increase in the number of cases of hip fracture with increasing age. There were significantly more women (57%) than men (43%). Univariate analysis identified protective effects for increased activity, exercise, calcium and vitamin supplements, almonds, fish, paneer (cottage cheese), curd (plain yogurt), and milk. However, tea and other caffeinated beverages were significant risk factors. In women, hormone/estrogen therapy appeared to have a marginal protective effect. For all cases, decreased agility, visual impairment, long term medications, chronic illnesses increased the risk of hip fracture. The multivariate analysis confirmed a protective effect of increased activity and also showed a decrease in hip fracture risk with increasing body mass index (odds ratio (OR) 0.024, 95% confidence interval (CI) 0.006-0.10 & OR 0.81, 95% CI 0.68-0.97 respectively). Individuals who take calcium supplements have a decreased risk of hip fracture (OR 0.076; CI 0.017-0.340), as do individuals who eat fish (OR 0.094; CI 0.020-0.431), and those who eat paneer (OR 0.152; 0.031-0.741). Tea drinkers have a higher risk of hip fracture (OR 22.8; 95% CI 3.73-139.43). Difficulty in getting up from a chair also appears to be an important risk factor for hip fractures (OR 14.53; 95% CI 3.86-54.23). CONCLUSIONS: In the urban Indian population, dietary calcium, vitamin D, increased body mass index, and higher activity levels have a significant protective effect on hip fracture. On the other hand, caffeine intake and decreased agility increase the risk of hip fracture. Future studies should be done in order to direct primary preventive programs for hip fracture in India.


Asunto(s)
Enfermedades Óseas Metabólicas/epidemiología , Fracturas de Cadera/epidemiología , Osteoporosis/epidemiología , Actividades Cotidianas , Anciano , Enfermedades Óseas Metabólicas/fisiopatología , Enfermedades Óseas Metabólicas/prevención & control , Cafeína/efectos adversos , Calcio de la Dieta/metabolismo , Estudios de Casos y Controles , Enfermedad Crónica/epidemiología , Comorbilidad , Suplementos Dietéticos , Ejercicio Físico/fisiología , Conducta Alimentaria/fisiología , Femenino , Fracturas de Cadera/fisiopatología , Fracturas de Cadera/prevención & control , Humanos , India/epidemiología , Masculino , Persona de Mediana Edad , Limitación de la Movilidad , Osteoporosis/fisiopatología , Osteoporosis/prevención & control , Aptitud Física/fisiología , Proyectos Piloto , Factores de Riesgo , Té/efectos adversos , Población Urbana/tendencias
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA